FN2 Earnings Intelligence
Gilead Sciences, Inc. income statement
Gilead Sciences, Inc. (GILD) Income Statement (annual) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $5,338 | $5,412 | $6,085 | $9,991 | $7,564 | - | - |
| + Debt | $26,695 | $25,230 | $24,987 | $26,711 | $24,936 | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $27,305 | $27,281 | $27,116 | $28,754 | $29,443 | $30,700.8 | $32,708.1 |
| % Growth | 10.6% | -0.1% | -0.6% | 6.0% | 2.4% | 4.3% | 6.5% |
| Gross Profit | $20,704 | $21,624 | $20,618 | $22,503 | $23,209 | - | - |
| % Margin | 75.8% | 79.3% | 76.0% | 78.3% | 78.8% | - | - |
| EBITDA | $10,247 | $7,653 | $7,959 | $2,043 | $10,392 | - | - |
| % Margin | 37.5% | 28.1% | 29.4% | 7.1% | 35.3% | - | - |
| Net Income | $6,225 | $4,592 | $5,665 | $480 | $8,510 | - | - |
| % Margin | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% | - | - |
| Diluted EPS | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 | -$0.46 | $9.89 |
| % Growth | 4,830.0% | -26.2% | 23.6% | -91.6% | 1,684.2% | -106.8% | 2,245.0% |
| Operating Cash Flow | $11,384 | $9,072 | $8,006 | $10,828 | $10,019 | - | - |
| CapEx | $579 | $728 | $585 | $523 | $563 | - | - |
| Free Cash Flow | $10,805 | $8,344 | $7,421 | $10,305 | $9,456 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $27,305 | $27,281 | $27,116 | $28,754 | $29,443 | $30,700.8 | $32,708.1 |
| Gross Profit | $20,704 | $21,624 | $20,618 | $22,503 | $23,209 | - | - |
| EBITDA | $10,247 | $7,653 | $7,959 | $2,043 | $10,392 | - | - |
| Net Income | $6,225 | $4,592 | $5,665 | $480 | $8,510 | - | - |
| Diluted EPS | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 | -$0.46 | $9.89 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $5,338 | $5,412 | $6,085 | $9,991 | $7,564 |
| Short-term Debt | $1,516 | $2,273 | $1,798 | $1,815 | $2,807 |
| Long-term Debt | $25,179 | $22,957 | $23,189 | $24,896 | $22,129 |
| Total Debt | $26,695 | $25,230 | $24,987 | $26,711 | $24,936 |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $11,384 | $9,072 | $8,006 | $10,828 | $10,019 |
| Capital Expenditure | $579 | $728 | $585 | $523 | $563 |
| Free Cash Flow | $10,805 | $8,344 | $7,421 | $10,305 | $9,456 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 10.6% | -0.1% | -0.6% | 6.0% | 2.4% |
| Gross Margin | 75.8% | 79.3% | 76.0% | 78.3% | 78.8% |
| EBITDA Margin | 37.5% | 28.1% | 29.4% | 7.1% | 35.3% |
| Net Margin | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% |
| FCF Margin | 39.6% | 30.6% | 27.4% | 35.8% | 32.1% |
| Diluted EPS Growth | 4,830.0% | -26.2% | 23.6% | -91.6% | 1,684.2% |